Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14446MR)

This product GTTS-WQ14446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3535MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ10474MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ328MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ9456MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ4979MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ11554MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ5069MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ5637MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW